Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.

Oncogene - 1 Jan 2021

von Felden Johann, Craig Amanda J, Garcia-Lezana Teresa, Labgaa Ismail, Haber Philipp K, D'Avola Delia, Asgharpour Amon, Dieterich Douglas, Bonaccorso Antoinette, Torres-Martin Miguel, Sia Daniela, Sung Max W, Tabrizian Parissa, Schwartz Myron, Llovet Josep M, Villanueva Augusto

Abstract excerpt

Little is known about the mutational landscape of advanced hepatocellular carcinoma (HCC), and predictive biomarkers of response to systemic therapies are lacking. We aimed to describe the mutational landscape of advanced HCC and to identify predictors of primary resistance to systemic therapies using circulating tumor DNA (ctDNA). We prospectively enrolled 121 patients between October 2015 and January 2019. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Immune Checkpoint Inhibitors

Share to Liver Neoplasms

Share to PTEN Phosphohydrolase

Share to Survival Analysis

Share to Telomerase

Source

Identifiers

PMID: 33097857
DOI: 10.1038/s41388-020-01519-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma.PMID 33097857Read ↗

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNASemantic proximity Read ↗

Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinomaSemantic proximity Read ↗

Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysisSemantic proximity Read ↗

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.Semantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular CarcinomaSemantic proximity Read ↗

Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.Semantic proximity Read ↗

Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancersSemantic proximity Read ↗

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.Semantic proximity Read ↗

Plasma Circulating Tumor DNA Sequencing Reveals the Landscape of Acquired Mutations in Patients with Hepatocellular Carcinoma: a Potential Predictive Value in Liquid BiopsySemantic proximity Read ↗

Circulating tumor DNA profiling reveals clonal evolution and real‐time disease progression in advanced hepatocellular carcinomaSemantic proximity Read ↗

TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.Semantic proximity Read ↗

Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.